« Back
Home /
Human PLAU/uPA Protein (active form) (PLA-HM101)

Human PLAU/uPA Protein (active form) (PLA-HM101)

Item no.	PLA-HM101-500UG
Manufacturer	KactusBio
Amount	500 ug
Quantity options	100 ug 500 ug
Category	Oncology Peptides & Proteins Recombinant Proteins By Organ Breast Cancer
Type	Proteins Recombinant
Format	Lyophilized
Specific against	Human (Homo sapiens)
Host	HEK293
Conjugate/Tag	HIS
Purity	> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Formula	Lyophilized from 0.22μm filtered solution in 25mM HEPES, 150mM NaCl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.
Sequence	Ser21-Leu431
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	PLAU,Urokinase,ATF,UPA,URK,u-PA,BDPLT5,QPD
Shipping Condition	Room temperature
Available
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	PLAU/uPA
Manufacturer - Conjugate / Tag	C-His
Shipping Temperature	Shipped at ambient temperature.
Storage Conditions	-20 to -80°C for 12 months as supplied from date of receipt.；-80°C for 3 months after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Molecular Weight	The protein has a predicted MW of 17.9 kDa (long chain A), 29.2 kDa (chain B) and 15.3 kDa (N-terminal fragment). The protein migrates to 30-38 kDa and 17 kDa based on Bis-Tris PAGE result.
Description	Recombinant Human PLAU/uPA Protein (active form) is expressed from HEK293 with His tag at the C-Terminus.It contains Ser21-Leu431, which consists of two chains: Long chain A (Ser21-Phe177) and chain B (Ile179-Leu431). The long chain A is further cleaved to yield a short chain A (Lys156-Phe177) and N-Terminus fragment (Ser21-Lys155).
Background	Plasminogen activator, urokinase (uPA) is a secreted serine protease, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin. Dysregulation of PLAU is often accompanied by various cancers and PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Lyophilized from 0.22 μm filtered solution in 1% HCOOH, 1 mM DTT (pH 3.0). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in 1% HCOOH, 1mM DTT (pH 3.0). It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500ug or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500ug or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Biotinylated	no

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

PLA-HM101-500UG-datasheet.pdf

PLA-HM101-500UG-safety-datasheet.pdf